# Molecular Biomarkers * **Definition:** Molecular biomarkers are biological molecules found in blood, other body fluids, or tissues that indicate a normal or abnormal process, or a condition or disease. They are used for diagnosis, prognosis, and monitoring of disease, as well as for predicting response to treatment. * **Taxonomy:** Healthcare Topics / Molecular Biomarkers ## News * Selected news on the topic of **Molecular Biomarkers**, for healthcare technology leaders * 7.1K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/29/2025 | [**North America Preventive Healthcare Technologies And Services Market Trends 2025**](https://www.linkedin.com/pulse/north-america-preventive-healthcare-technologies-tfraf/) | [[Linkedin]] | | 5/5/2025 | [**Harnessing AI and Cloud Technologies for Breakthroughs in Disease Research - Medium**](https://medium.com/@chaitrann.chakilam/harnessing-ai-and-cloud-technologies-for-breakthroughs-in-disease-research-d54de03a45cb) | [[Medium]] | | 2/19/2025 | [**YourBio Health Strengthens Leadership Team to Propel Next Phase of Growth**](https://www.prnewswire.com/news-releases/yourbio-health-strengthens-leadership-team-to-propel-next-phase-of-growth-302379735.html) | [[PR Newswire]] | | 1/25/2025 | [**Health IT Product News Report January 2025**](https://www.healthitanswers.net/health-it-product-news-report-january-2025/) | [[Health IT Answers]] | | 1/22/2025 | [**ActiGraph Accelerates Clinical Trial Modernization With Transformational Acquisition Of ...**](https://www.clinicalleader.com/doc/actigraph-accelerates-clinical-trial-modernization-with-transformational-acquisition-of-biofourmis-life-science-business-0001) | [[Clinical Leader]] | | 1/22/2025 | [**ActiGraph Accelerates Clinical Trial Modernization With Transformational Acquisition Of ...**](http://www.clinicalleader.com/doc/actigraph-accelerates-clinical-trial-modernization-with-transformational-acquisition-of-biofourmis-life-science-business-0001) | [[Clinical Leader]] | | 1/22/2025 | [**AI model predicts blood transfusion needs in ICU patients - News-Medical**](https://www.news-medical.net/news/20250122/AI-model-predicts-blood-transfusion-needs-in-ICU-patients.aspx) | [[News Medical Net]] | | 1/16/2025 | [**Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trends - Technavio**](https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-to-grow-by-usd-13-7-billion-from-2025-2029--driven-by-novel-approvals-with-ai-impacting-market-trends---technavio-302351407.html) | [[PR Newswire]] | | 1/9/2025 | [**OMNY Health and Scipher Medicine Partner to Revolutionize Autoimmune Disease ...**](https://www.businesswire.com/news/home/20250109865071/en/OMNY-Health-and-Scipher-Medicine-Partner-to-Revolutionize-Autoimmune-Disease-Treatment-with-Clinico-Transcriptomics-Data) | [[Business Wire]] | | 1/7/2025 | [**ActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science Business**](https://www.prnewswire.com/news-releases/actigraph-accelerates-clinical-trial-modernization-with-transformational-acquisition-of-biofourmis-life-science-business-302344216.html) | [[PR Newswire]] | | 1/7/2025 | [**ActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of ...**](https://finance.yahoo.com/news/actigraph-accelerates-clinical-trial-modernization-110000990.html) | [[Yahoo Finance]] | | 12/30/2024 | [**Precision Medicine Software Research Analysis Report 2024-2030: Increasing Adoption of Genomic Data Analysis Software Spurs Growth, Integration of Multi-Omics Data Strengthens the Business Case - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241230952002/en/Precision-Medicine-Software-Research-Analysis-Report-2024-2030-Increasing-Adoption-of-Genomic-Data-Analysis-Software-Spurs-Growth-Integration-of-Multi-Omics-Data-Strengthens-the-Business-Case---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/30/2024 | [**Precision Medicine Software Research Analysis Report 2024-2030: Increasing Adoption of Genomic Data Analysis Software Spurs Growth, Integration of Multi-Omics Data Strengthens the Business Case - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241230952002/en/Precision-Medicine-Software-Research-Analysis-Report-2024-2030-Increasing-Adoption-of-Genomic-Data-Analysis-Software-Spurs-Growth-Integration-of-Multi-Omics-Data-Strengthens-the-Business-Case---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/11/2024 | [**Anasens: Appointment of Pierre Fitzgibbon to the Board of Directors - Business Wire**](https://www.businesswire.com/news/home/20241211465784/en/Anasens-Appointment-of-Pierre-Fitzgibbon-to-the-Board-of-Directors) | [[Business Wire]] | | 12/11/2024 | [**Anasens: Appointment of Pierre Fitzgibbon to the Board of Directors**](http://www.businesswire.com/news/home/20241211465784/en/Anasens-Appointment-of-Pierre-Fitzgibbon-to-the-Board-of-Directors/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/11/2024 | [**Anasens: Appointment of Pierre Fitzgibbon to the Board of Directors**](https://www.businesswire.com/news/home/20241211465784/en/Anasens-Appointment-of-Pierre-Fitzgibbon-to-the-Board-of-Directors/) | [[Business Wire]] | | 12/6/2024 | [**Roundup: AI partnerships aim to advance cardiac radiology, gynecology, more**](https://www.healthcareitnews.com/news/roundup-ai-partnerships-aim-advance-cardiac-radiology-gynecology-more) | [[Healthcare IT News]] | | 12/5/2024 | [**Digital Pathology Solution Market Overview: Future Growth Trends and Opportunities with ...**](https://www.linkedin.com/pulse/digital-pathology-solution-market-overview-future-growth-x0fuf) | [[Linkedin]] | | 12/2/2024 | [**Next Generation Cancer Diagnostics Business Research Report 2024-2030: Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241202011489/en/Next-Generation-Cancer-Diagnostics-Business-Research-Report-2024-2030-Technological-Advancements-in-ctDNA-CTC-and-Circulating-miRNA-Testing-Propel-Market-Growth---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/1/2024 | [**Xtalks Announces its Life Science Webinar Calendar for November 2024**](https://www.prweb.com/releases/xtalks-announces-its-life-science-webinar-calendar-for-november-2024-302293808.html) | [[PRWeb]] | | 10/1/2024 | [**Xtalks Announces its Life Science Webinar Calendar for October 2024 - PRWeb**](https://www.prweb.com/releases/xtalks-announces-its-life-science-webinar-calendar-for-october-2024-302263930.html) | [[PRWeb]] | | 9/1/2024 | [**Xtalks Announces its Life Science Webinar Calendar for September 2024**](https://www.prweb.com/releases/xtalks-announces-its-life-science-webinar-calendar-for-september-2024-302235364.html) | [[PRWeb]] | | 8/1/2024 | [**Xtalks Announces its Life Science Webinar Calendar for August 2024 - PRWeb**](https://www.prweb.com/releases/xtalks-announces-its-life-science-webinar-calendar-for-august-2024-302211920.html) | [[PRWeb]] | | 7/25/2024 | [**Digital Biomarkers Market Size to Hit USD 43.3 Billion by 2034, Projected a 31.4% CAGR**](https://www.prnewswire.com/news-releases/digital-biomarkers-market-size-to-hit-usd-43-3-billion-by-2034--projected-a-31-4-cagr--report-by-transparency-market-research-inc-302205304.html) | [[PR Newswire]] | | 6/13/2024 | [**Flinn Foundation-Sponsored Study Identifies Three Bioscience Growth Areas to Advance Innovation and Economic Growth in Greater Phoenix**](http://www.businesswire.com/news/home/20240613324046/en/Flinn-Foundation-Sponsored-Study-Identifies-Three-Bioscience-Growth-Areas-to-Advance-Innovation-and-Economic-Growth-in-Greater-Phoenix/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **BioAI**: Focuses on biomarker discovery and diagnostics using artificial intelligence. - **Caris Life Sciences**: Provider of advanced molecular profiling services that assess DNA, RNA, and proteins to tailor cancer treatments. - **Meaningful Insights Biotech Analytics (MiBA)**: A company specializing in AI technologies and oncology data, aiming to enhance precision medicine and biomarker testing. - **BostonGene**: A company recognized for its AI-powered platforms that enhance cancer diagnostics and treatment through advanced technologies. - **Quibim**: An AI-powered imaging biomarker company aiming to enhance precision medicine through actionable insights from imaging scans. - **Promise Bio**: A startup focused on precision medicine for immune-mediated diseases, developing a computational platform that integrates epiproteomics and AI to predict patient treatment responses. - **Abbott Laboratories**: A global healthcare company involved in the development of molecular diagnostics and companion diagnostics. - **Guardant Health**: Specializes in blood-based cancer diagnostics and monitoring through advanced genomic testing. - **Roche**: A major player in the diagnostics market, focusing on personalized medicine and molecular diagnostics. - **Wren Laboratories**: A company focusing on in-vitro diagnostic technologies and AI/ML liquid biopsy genomic assays. - **Agilent**: A leader in life sciences, diagnostics, and applied chemical markets, contributing to molecular diagnostics. - **OneCell Diagnostics**: A genomics-based precision oncology company focused on making cancer diagnostics more accessible and actionable. - **Canary Speech Inc.**: A startup focused on using biomarkers to assess and track mental health and neurological disorders. - **iXpressGenes**: A company launching the Trauma Autoimmune Indicator (TAI) test to detect trauma-induced diseases, aiming to shift from reactive to preventative care. - **Paige**: A company that has developed Paige Alba, a clinical-grade multimodal co-pilot for personalized medicine and precision oncology. - **Mount Sinai**: Developed the SCORPIO model, a machine learning tool predicting immune checkpoint inhibitor responses using routine clinical data. - **OMNY Health**: A healthcare data ecosystem provider that integrates clinical data with genomic insights to enhance precision medicine for autoimmune diseases. ### Partnerships and Collaborations - **BioAI and Genomic Testing Cooperative**: Collaborating to improve biomarker discovery and diagnostics using multimodal AI. - **Guardant Health and MiBA**: A partnership aimed at enhancing precision medicine through improved biomarker testing and data analytics, leveraging AI technologies and tumor profiling. - **MGI Tech and Predica Diagnostics**: Collaborating to develop targeted RNA sequencing tests for early cancer detection. - **BostonGene and Various Institutions**: Collaborating to enhance personalized cancer care through AI-driven multiomics platforms. - **Guardant Health and Meaningful Insights Biotech Analytics**: Formed a partnership to enhance precision medicine through improved biomarker testing and data analytics. - **Juniper Biologics and Caris Life Sciences**: Collaboration to enhance patient access to personalized treatment options in the Middle East and Africa through advanced molecular profiling. - **Quibim**: Has established partnerships with major healthcare institutions to enhance its AI-powered imaging biomarkers. - **Onco-Innovations and Quantify Research**: Exploring collaboration in advanced data analytics and oncology research to enhance cancer treatment insights. - **BioNexus Gene Lab Corp. and Shenzhen Rongguang Health Group**: Strategic partnership to enhance cancer screening and precision medicine in Southeast Asia. - **OMNY Health and Scipher Medicine**: Collaborating to integrate transcriptomic data with EHR to improve understanding and treatment of autoimmune diseases. - **Promise Bio and AstraZeneca/Pfizer**: Promise Bio received funding to enhance its technology and build a post-translational modification database. - **Genoks and Velsera**: Partnered to enhance cancer diagnostics in Turkey by integrating Velsera's Clinical Genomics Workspace. - **ZEISS and Mindpeak**: Collaborating to create an integrated Multiplex Immunofluorescence solution to enhance pathology workflows. - **Lunit and Various Institutions**: Partnering to advance digital pathology and cancer diagnostics through AI. - **NEC X and General Prognostics Inc.**: Collaboration to improve chronic disease management through a non-invasive heart failure monitoring device. - **NEC X and GPx**: Investing in GPx to enhance chronic disease monitoring and improve healthcare access. - **Talkspace and Wisdo Health**: Partnering to improve mental health resources for seniors, integrating therapy services with peer support communities. ### Innovations, Trends, and Initiatives - **Multi-Marker Diagnostic Tests**: Focus on developing comprehensive tests that analyze multiple biomarkers for better insights. - **Digital Biomarkers Market Growth**: The digital biomarkers market is projected to grow significantly, driven by the increasing prevalence of chronic diseases and demand for real-time health data. - **Advancements in Next-Generation Sequencing**: Technological innovations in sequencing are driving growth in molecular diagnostics and personalized medicine. - **Liquid Biopsy Technologies**: OneCell Diagnostics is launching a next-generation liquid biopsy test to provide actionable biomarkers for cancer. - **Next-Generation Sequencing (NGS)**: Advancements in NGS technologies are revolutionizing genomic analysis, making it more accessible and enabling the identification of actionable biomarkers. - **PROMISE Platform**: Utilizes advanced data-driven tools to identify predictive biomarkers for personalized therapies in autoimmune diseases. - **MarketsandMarkets ImmunoBio Series**: An upcoming conference focusing on biomarkers and immuno-oncology, promoting collaboration among industry leaders. - **Liquid Biopsy Tests**: A shift towards non-invasive testing methods for cancer detection, enhancing patient comfort and accessibility. - **Next Generation Cancer Diagnostics (NGCD)**: The market is projected to grow significantly, driven by advancements in personalized medicine and liquid biopsy technologies. - **SCORPIO Model**: A machine learning tool that predicts responses to immune checkpoint inhibitors, outperforming existing biomarkers. - **uIHC AI Model by Lunit**: A novel AI model that enhances biomarker formation from immunohistochemistry, improving cancer diagnostics. - **Hoag Compass**: A new primary care program emphasizing proactive healthcare and personalized care plans based on over 100 biomarkers. - **AI in Cancer Care**: BostonGene's AI-driven platforms optimize drug development and clinical trials, facilitating personalized cancer care. - **Protein Sequencing Market Growth**: Valued at $1.74 billion in 2023, expected to grow to $2.69 billion by 2033, driven by personalized medicine. - **TAI Test**: Aims to detect trauma-induced diseases early, marking a shift towards preventative care in trauma management. - **AI in Healthcare**: AI technologies are being integrated into healthcare for improved diagnostics, patient monitoring, and personalized treatment strategies, particularly in oncology. - **Integration of AI in Diagnostics**: Current trends include the use of AI and machine learning in diagnostic tools to improve accuracy and efficiency. - **AI and Big Data in Clinical Research**: 49% of pharmaceutical companies are utilizing AI and Big Data, indicating a trend towards digital tools in clinical research. ### Challenges and Concerns - **Market Growth Barriers**: Challenges such as inadequate medical reimbursements may hinder the expansion of molecular diagnostics. - **High Development Costs**: The financial burden associated with developing new molecular diagnostics can hinder innovation. - **Market Saturation**: Potential saturation in the COVID-19 molecular diagnostics market poses challenges for future growth. - **Underutilization of Innovative Trial Methodologies**: Despite the promising uptake of biomarkers, adaptive trial designs and master protocols are not widely implemented. - **Data Privacy and Regulatory Issues**: Concerns regarding data privacy, regulatory compliance, and the need for robust frameworks to ensure responsible use of AI and digital biomarkers. - **Access to Genomic Testing**: Ensuring broad access to genomic testing remains a challenge, as disparities in healthcare access can affect patient outcomes. - **Cost and Validation Difficulties**: Identified as major roadblocks in adopting innovative tools for neurodegenerative clinical research. - **Evolving Virus Strains**: The emergence of new strains can complicate the effectiveness of existing diagnostic tests. - **Regulatory Requirements**: Stringent regulations can slow down the approval process for new diagnostic tests. - **Data Privacy and Compliance**: Concerns regarding the integration of real-world data in predictive modeling for cancer treatment. - **High Costs of Gene Therapies**: The development of gene therapies poses financial challenges, prompting companies to seek innovative and affordable treatment solutions. - **Regulatory Constraints**: The transition to open-source tools in clinical data analysis faces challenges due to regulatory compliance and support issues. - **Regulatory Implications**: Concerns regarding the long-term effects of pricing regulations on drug development and patient access to treatments. - **Digital Adoption Challenges**: Concerns regarding patient safety, data integrity, and regulatory compliance are hindering broader digital adoption in healthcare. ## Related Topics [[Molecular Diagnostics]]; [[Digital Biomarkers]]; [[Molecular Biology]]